Jennifer Doudna (UC Berkeley Professor) – Genome Editing with CRISPR-Cas Systems (Dec 2019)
Chapters
00:00:45 CRISPR-Cas9: A Journey from Curiosity-Driven Science to Genome Editing
Background and Early Life: Jennifer Doudna showed a passion for nature and developed a deep appreciation for the environment during her youth in Hawaii. Her father encouraged her intellectual curiosity and fostered her interest in science, inspiring her to pursue challenging scientific endeavors.
Academic and Research Career: Jennifer excelled as an undergraduate at Pomona College and went on to Harvard Medical School for her PhD, where she worked with Jack Shostak on innovative projects related to the origins of life and RNA as an enzyme. She continued her research at Tom Cech’s lab at the University of Colorado, Boulder, further exploring RNA as enzymes. Jennifer joined the faculty at Yale University and eventually moved to the University of California, Berkeley.
Discovery and Development of CRISPR-Cas9: Jennifer possessed a unique ability to recognize the potential of the bacterial immune system, CRISPR-Cas9, as a tool for genome editing, when others did not. She deciphered the mechanism by which this RNA-directed protein could be used for precise genome editing. Jennifer enthusiastically promoted the potential of CRISPR-Cas9, collaborating with colleagues and sharing her findings with the scientific community.
Awards and Recognition: Jennifer’s pioneering work on CRISPR-Cas9 garnered her numerous prestigious awards and accolades.
Generosity and Advocacy: Jennifer demonstrated generosity in her approach to science, aiming to share knowledge and make scientific advancements accessible to all. She actively advocated for the responsible and ethical deployment of CRISPR-Cas9 technology, emphasizing the importance of using it for the benefit of society.
CRISPR-Cas9: Opportunities and Challenges: Jennifer highlighted the immense potential of CRISPR-Cas9 technology for genome editing and its applications in various fields, including medicine, agriculture, and basic research. She also acknowledged the challenges associated with this technology, such as potential ethical concerns and the need for careful regulation to ensure its responsible use.
Background: Jennifer Doudna and Jillian Banfield initiated a unique collaboration to study a novel bacterial immune system called CRISPR. CRISPR allows bacteria to defend themselves against viruses by capturing and storing fragments of viral DNA in their genome.
CRISPR Mechanism in Bacteria: During viral infection, bacteria can capture viral DNA and store it in a CRISPR array. The CRISPR array is transcribed into RNA molecules, which then combine with Cas proteins to form RNA-guided proteins. These RNA-guided proteins search the cell for matching DNA sequences and cut them up, protecting the cell from viral infection.
Collaboration with Emmanuelle Charpentier: Doudna met Emmanuelle Charpentier at a conference and decided to collaborate on studying a new type of CRISPR system found in bacteria that infect humans. Charpentier’s interest in this bacterium was as an infectious agent in humans.
Significance: This collaboration laid the foundation for the development of CRISPR-Cas9 gene editing technology, revolutionizing the field of genome engineering and leading to numerous applications in research and medicine.
00:12:09 Discovery of Programmable DNA Cleavage by Cas9
Background: Jennifer Doudna and Emanuel Charpentier collaborated to study the Cas9 protein, an RNA-guided enzyme involved in bacterial immunity.
Discovery of Cas9’s Mechanism: Cas9 utilizes its RNA guide to interact with double-stranded DNA in the cell at a sequence matching the 20 letters of the RNA. This interaction allows Cas9 to make a double-stranded break in DNA, effectively cutting both strands of the DNA molecule at a precise position.
Collaborative Effort: Martin Yinek and Chris Chylinski, researchers from Doudna’s and Charpentier’s labs, worked together to elucidate the enzyme’s mechanism and its ability to use two RNA molecules for guided DNA cleavage.
Development of the Single Guide: A crucial step in the research was the creation of a single guide RNA, linking two separate RNA molecules into a single entity. This single guide RNA carries the necessary information for DNA recognition on one end and a handle for interaction with Cas9 on the other.
Single Guide Experiment: Martin Yinek conducted a key experiment demonstrating that the single guide RNA could program Cas9 to cleave specific DNA molecules in the laboratory.
Potential for Genome Editing: The discovery of Cas9’s DNA cleavage mechanism led to the realization that this system could be used for genome editing, opening up exciting possibilities for manipulating DNA in plant, animal, and human cells.
DNA Repair in Plant and Animal Cells: Unlike bacteria, plant and animal cells respond to double-stranded DNA breaks by triggering DNA repair mechanisms. This characteristic makes it possible to utilize Cas9-mediated DNA cleavage for genome editing purposes.
00:15:19 CRISPR: A Revolution in Genome Editing and Its Impact on Science, Public Health
Origins and Discovery of CRISPR: CRISPR-Cas9, a bacterial genome editing system, emerged as a groundbreaking tool for precise genetic modifications. Scientists recognized that the key to targeted genome editing was the ability to induce double-stranded breaks at desired positions. Cas9, an RNA-guided protein from bacteria, was identified as a programmable enzyme capable of cutting DNA at specific locations.
CRISPR as a Genome Editing Tool: CRISPR-Cas9 can efficiently search and bind to DNA sequences matching the guide RNA. The enzyme forms a complex with the DNA, leading to a double-stranded break and triggering DNA repair mechanisms. This process enables targeted changes to the DNA sequence, including insertions, deletions, or precise modifications.
Opportunities and Challenges: CRISPR has revolutionized research, allowing scientists to study organisms previously inaccessible for genetic analysis. In public health, gene drives driven by CRISPR can be used to spread beneficial traits rapidly through populations, potentially controlling disease vectors or eradicating infectious diseases.
Applications in Biomedical Science: CRISPR holds promise in clinical medicine for correcting genetic defects, treating diseases, and potentially curing genetic disorders. Ongoing research aims to harness CRISPR’s capabilities for personalized medicine and targeted therapies.
Convergence of Technologies: CRISPR complements other breakthroughs in genomics, DNA sequencing, and molecular imaging, creating an unprecedented toolbox for scientific inquiry. The convergence of these technologies enables scientists to ask novel questions and explore uncharted territories in biology.
Exciting Prospects for the Future: CRISPR has sparked immense excitement in the scientific community due to its potential to address fundamental research questions, improve public health, and revolutionize biomedical science. The field is rapidly evolving, with ongoing research and discoveries promising even greater impact in the years to come.
Gene Drives: CRISPR gene drives raise ethical concerns due to potential public health benefits and unintended environmental impacts.
Agriculture: CRISPR can manipulate genes in plants to control fruit production and yield, with potential applications in food production worldwide.
Diagnostics: CRISPR-Cas enzymes can be used for diagnostics, detecting specific DNA sequences, including viral or bacterial infections and tumor development.
Somatic vs. Germ Cell Genome Editing: Genome editing can be performed in somatic cells (non-heritable changes affecting only an individual) or germ cells (heritable changes affecting offspring).
Somatic Cell Applications: Most biomedical applications of genome editing will likely be in somatic cells, affecting individuals and not future generations.
Curing Genetic Diseases: CRISPR can potentially cure genetic diseases by correcting mutations in somatic cells, offering hope for treating long-known diseases.
00:30:35 Germline Editing: Ethical Considerations and Potential Applications
Genetic Cause of Sickle Cell Disease: Sickle cell disease is caused by a single mutation in the DNA of the human genome, leading to an altered protein sequence in beta globin. The mutant protein forms sickled cells that occlude capillaries, causing various health problems.
CRISPR-Cas9 as a Potential Cure for Sickle Cell Anemia: CRISPR-Cas9 technology offers a promising approach to treat genetic diseases like sickle cell anemia. Scientists are developing gene therapies using CRISPR-Cas9 to correct or mitigate the disease-causing mutation. Clinical trials are underway to evaluate the effectiveness and safety of CRISPR-Cas9-based gene therapies for sickle cell disease.
Heritable Gene Editing: Heritable gene editing, also known as germline editing, involves making changes in the DNA of an animal or organism that can be passed on to future generations. CRISPR-Cas9 has been successfully used for germline editing in mice, enabling the creation of animal models for human diseases. The potential application of germline editing in humans raises ethical and societal concerns.
Ethical Considerations and Scientific Responsibility: Jennifer Doudna initially felt uncomfortable with the idea of manipulating human DNA in embryos, recognizing the profound implications of altering human genetics. She emphasizes the responsibility of scientists to embrace and engage in discussions about the ethical, societal, and legal aspects of emerging technologies like CRISPR-Cas9. Scientists should actively participate in shaping the ethical guidelines and regulations surrounding the use of genome editing technologies.
00:37:43 International Concerns Surrounding CRISPR-Cas9 and Human Genome Editing
1. International Meetings and Reports on Human Genome Editing: Following the publication in Science Magazine proposing a prudent path forward with CRISPR-Cas9, particularly for human and human germline applications, Fyodor Urnov and colleagues published a paper expressing similar concerns about human germline editing. The National Academies of Science and the Royal Society in the UK organized international meetings and produced a report on human genome editing, especially human germline editing, to address the challenges and ethical implications of manipulating DNA in human embryos.
2. Global Scientific Community’s Response: The scientific community globally aimed to grapple with the complex question of how to responsibly use CRISPR-Cas9, a powerful tool that could fundamentally alter human genetics and populations. Many scientists hoped that guidelines would be established and respected, discouraging the application of CRISPR-Cas9 in the human germline before thorough evaluation and understanding of the potential consequences.
3. Surprise and Shock at Human Germline Editing Attempt: In November 2018, Jennifer Doudna received an email from a researcher informing her about an attempt to use CRISPR-Cas9 for human germline editing. This incident highlighted the urgency of addressing the ethical and societal implications of human germline editing, given the potential consequences for future generations.
00:40:09 CRISPR-Cas9: Misuse, Regulation, and Future Advancements
CRISPR Babies: A Flawed Study: Dr. He Jiankui announced the use of CRISPR-Cas9 to modify the DNA of twin baby girls in China, purportedly to protect them from HIV infection. Details revealed at a human genome editing conference in Hong Kong highlighted severe flaws in the study.
Scientific Inadequacies: Data presented by Dr. He showed that the genetic changes introduced in the baby girls differed from natural mutations associated with HIV resistance. The alterations made had not been observed in the human population or tested in animals, raising concerns about their safety and efficacy.
Ethical Concerns: The study faced criticism for its questionable ethics, including the consent process with the parents and the potential risks to the children.
Importance of Responsible Use: The incident underscored the need for stricter controls and regulations to prevent irresponsible uses of CRISPR technology. Efforts are underway by international commissions to develop frameworks for responsible use and future regulations.
Advancing Genome Editing Tools: Key areas of focus for future breakthroughs include improving genome manipulation tools, targeted delivery of gene editors into cells, and ensuring their accuracy and efficiency.
00:46:10 Genome Engineering: Expanding the Toolkit for Precise Manipulations
Base Editing: Chemical changes to a single nucleotide in DNA without triggering a cut using Cas9.
Genome Mutagenization: Targeted mutagenesis of a genomic region to create various gene variants for laboratory testing.
Prime Editing: Introduction of single nucleotide polymorphisms (SNPs) for targeted rewrites in a specific genome section.
CRISPR-Cas9 Protein Variants: Continuous development of Cas9 variants for various genome manipulation tasks.
Rapid Pace of Development: Constant evolution of CRISPR-based tools in real time in laboratories.
Recent Advancements: Exciting progress showcased at a recent Cold Spring Harbor conference.
Global Collaboration: Rapid sharing and improvement of CRISPR tools by scientists worldwide.
Precision Genome Editing: Near-future possibility of making precise changes in any genome.
Cell Type Specific Editing: Current focus on targeted genome editing in specific cell populations and tissues.
Delivery Challenges: Ongoing research on effective delivery of genome editors to desired cells.
00:50:31 Breakthroughs in CRISPR-Cas9 Delivery Methods
The Importance of Innovation in Delivery: Innovation is crucial for addressing the delivery challenges of genome editing. The Innovative Genomics Institute at Berkeley and UCSF is actively working on finding solutions to this problem. No single solution will suffice, and various approaches are being explored.
Tyrosinase-Enabled Linking of Proteins: Researchers have developed a method to link CRISPR-Cas9 with cell-penetrating peptides using tyrosinase, an enzyme. This technique allows efficient genome editing without the need for additional cell manipulation.
Virus Capsid-Mediated Delivery: Scientists are harnessing the natural ability of viruses to target specific cell types for CRISPR-Cas9 delivery. Viral capsids can be modified to remove infectious genes while retaining their cell-entry capabilities. Recent experiments have demonstrated the selective editing of immune cells using virus-like particles.
Clinical Applications on the Horizon: CRISPR-Cas9 has shown promise in treating blood disorders such as sickle cell disease and beta thalassemia. Clinical trials have demonstrated the safety and efficacy of CRISPR-Cas9 in editing immune cells for cancer patients.
Ongoing Research and Developments: Efforts continue to expand the toolbox of CRISPR-Cas proteins and RNA-guided gene regulation. Researchers are investigating delivery and control mechanisms, including chemical, societal, and regulatory aspects. Exploration of new CRISPR systems and beyond is underway in collaboration with Jill Banfield’s lab.
Conclusion: The field of genome editing is rapidly evolving, with exciting developments in delivery methods and clinical applications. Ongoing research and collaboration hold the promise of further breakthroughs in the future.
Abstract
Revolutionizing Biology: The CRISPR-Cas9 Story
Jennifer Doudna’s remarkable journey with CRISPR-Cas9, a groundbreaking genome editing technology, represents a paradigm shift in biological research and medicine. Stemming from her early fascination with nature and bolstered by academic excellence, Doudna’s discovery and development of CRISPR-Cas9 have opened new avenues in genetic research, disease treatment, and agricultural advancements. This article delves into Doudna’s path, the evolution of CRISPR technology, its profound implications, and the ethical considerations it brings to the forefront.
Jennifer Doudna’s Ascent in Science
Renowned for her pioneering work on CRISPR-Cas9, Jennifer Doudna’s journey in science was fueled by a deep-rooted curiosity about nature and a supportive environment created by her father. Her academic prowess, evidenced by her degrees from Pomona College and Harvard Medical School, laid the foundation for her future contributions. Collaborations with Nobel laureates Jack Shostak and Tom Cech in RNA research were pivotal in her journey towards groundbreaking discoveries.
CRISPR-Cas9: A Transformative Technology
CRISPR-Cas9’s ability to precisely edit DNA has revolutionized the study of gene function and disease mechanisms. Its applications extend from treating genetic disorders to advancing personalized medicine. The technology’s potential emerged from Doudna’s curiosity about bacterial immune systems, leading to its conceptualization as a versatile tool for genome editing. Her commitment to collaboration and ethical deployment has been a consistent theme in her work.
Background and Early Life
Jennifer Doudna’s passion for nature and deep appreciation for the environment were nurtured during her youth in Hawaii. Her father played a crucial role in encouraging her intellectual curiosity and fostering her interest in science, which motivated her to pursue challenging scientific endeavors.
Academic and Research Career
Jennifer’s academic journey started with her undergraduate studies at Pomona College, followed by a PhD from Harvard Medical School. Here, she worked with Jack Shostak on groundbreaking projects related to the origins of life and RNA’s enzymatic functions. She continued her research at Tom Cech’s lab at the University of Colorado, Boulder, delving deeper into RNA enzymes. Jennifer’s academic path then led her to Yale University and eventually to the University of California, Berkeley, where she furthered her research.
Discovery and Development of CRISPR-Cas9
Jennifer Doudna’s initial research with Jillian Banfield unraveled bacterial defense mechanisms, shedding light on RNA-guided proteins and their critical role in DNA cleavage, a key feature of CRISPR functionality. Her collaboration with Emmanuelle Charpentier further demystified the molecular basis of CRISPR systems, leading to the development of a single guide RNA, simplifying CRISPR’s mechanism and paving the way for programmable genome editing.
Unraveling the CRISPR System: A Collaborative Journey into Bacterial Immunity and Genome Editing
Doudna and Jillian Banfield embarked on a collaborative study of CRISPR, a novel bacterial immune system. They explored how bacteria defend themselves against viruses by capturing and storing viral DNA. This defense mechanism involves the transcription of the CRISPR array into RNA molecules that, combined with Cas proteins, form RNA-guided proteins. These proteins search for and destroy matching viral DNA, safeguarding the cell.
CRISPR-Cas9 and DNA Cleavage
Doudna and Emanuel Charpentier’s collaboration focused on the Cas9 protein, a key player in bacterial immunity. Cas9 utilizes RNA guides to identify and cleave double-stranded DNA at specific sequences. This mechanism, elucidated by Martin Yinek and Chris Chylinski from Doudna’s and Charpentier’s labs, highlighted Cas9’s ability to make precise cuts in DNA.
CRISPR: A Dawn of Programmable Genome Editing
The advent of CRISPR-Cas9 as a genome editing tool marked a significant milestone in scientific research, offering precise DNA manipulation capabilities. Despite its potential in various fields, its application in human germline editing raised ethical concerns, prompting discussions among scientists and bioethicists. The fusion of CRISPR with other technologies like DNA sequencing has expanded its impact, opening new research and application possibilities.
Wide-Ranging Applications and Ethical Considerations
CRISPR’s diverse applications range from public health to agriculture and biomedical diagnostics. In biomedical applications, somatic cell editing shows promise in curing diseases like sickle cell anemia. However, germline editing, which can permanently alter the human genetic makeup, raises profound ethical and safety questions.
Sickle Cell Anemia: A Case Study in CRISPR’s Potential
CRISPR-Cas9’s potential in treating genetic disorders is highlighted in its application to sickle cell anemia, a disease caused by a single gene mutation. CRISPR-Cas9’s ability to precisely target and modify this mutation offers hope for curing this debilitating condition. This approach emphasizes the distinction between somatic and germline editing, underscoring the need for responsible scientific conduct and regulatory frameworks.
The Ethical Landscape and Global Response
The ethical debate surrounding CRISPR-Cas9, especially in human germline editing, intensified following He Jiankui’s controversial human embryo experiment. The scientific community has responded with calls for international collaboration and guidelines to ensure responsible use. The World Health Organization and National Academies have played key roles in leading these efforts.
Advancements and Future Prospects in Genome Editing
The CRISPR-Cas9 toolbox continues to evolve with innovations like base and prime editing enhancing precision. Addressing the challenge of delivering genome editors to specific cells remains a focus area, with potential solutions including cell-penetrating peptides and engineered virus capsids. Early clinical trials highlight CRISPR-Cas9’s potential in treating diseases, though its efficacy and safety continue to be evaluated.
Origins and Discovery of CRISPR
CRISPR-Cas9, originating as a bacterial genome editing system, has become a revolutionary tool for precise genetic modifications. Scientists recognized the ability to induce double-stranded breaks at specific locations as crucial for targeted genome editing. Cas9, an RNA-guided protein from bacteria, emerged as a programmable enzyme capable of precisely cutting DNA.
CRISPR as a Genome Editing Tool
CRISPR-Cas9’s efficiency in searching and binding to DNA sequences matching the guide RNA has been a game-changer. The enzyme forms a complex with DNA, creating double-stranded breaks and initiating DNA repair mechanisms. This enables targeted DNA sequence alterations, including insertions, deletions, or specific modifications.
Opportunities and Challenges
CRISPR has revolutionized research, enabling the study of organisms previously inaccessible for genetic analysis. In public health, gene drives powered by CRISPR could rapidly spread beneficial traits through populations, potentially controlling disease vectors or eradicating infectious diseases.
Applications in Biomedical Science
CRISPR’s promise in clinical medicine lies in its potential to correct genetic defects and treat diseases, offering hope for curing genetic disorders. Research is focused on harnessing CRISPR’s capabilities for personalized medicine and targeted therapies.
Convergence of Technologies
CRISPR complements other breakthroughs in genomics, DNA sequencing, and molecular imaging, forming an unprecedented scientific toolbox. This convergence allows scientists to explore new questions and territories in biology.
Exciting Prospects for the Future
CRISPR’s potential has generated immense excitement in the scientific community, with implications for fundamental research, public health, and biomedical science. The field is rapidly evolving, with ongoing research promising even greater impact.
Supplemental Update: CRISPR-Cas9 and the Ethical Implications of Human Germline Editing
Following a proposal in Science Magazine for a prudent approach to CRISPR-Cas9, especially in human applications, Fyodor Urnov and colleagues echoed concerns about human germline editing. The National Academies of Science and the Royal Society in the UK organized international meetings and produced a report on human genome editing, focusing on the challenges and ethical implications of manipulating DNA in human embryos.
The global scientific community is grappling with how to use CRISPR-Cas9 responsibly, particularly in human genetics. There’s a consensus on establishing and adhering to guidelines to prevent premature use in the human germline before fully understanding potential consequences. Jennifer Doudna’s shock at learning about attempts at human germline editing in November 2018 underscored the need for urgent ethical considerations.
CRISPR Controversies and Future Directions
Dr. He Jiankui’s announcement of using CRISPR-Cas9 on twin baby girls in China to potentially confer HIV resistance was marred by scientific and ethical flaws. The study faced criticism for potential risks and the questionable consent process. This incident highlighted the necessity for stringent controls and responsible use of CRISPR technology. Efforts are underway to develop frameworks for its use and future regulations, focusing on improving genome manipulation tools, targeted delivery, accuracy, and efficiency.
Rapid Evolution of CRISPR-Based Genome Editing Technologies
CRISPR-Cas9 applications have expanded to include precise genome editing, transcription control, and gene output manipulation. Innovations like base editing and prime editing have enhanced precision. The rapid development of CRISPR tools, as showcased at a recent Cold Spring Harbor conference, emphasizes the continuous evolution of these technologies. Global collaboration is key in refining and improving these tools for specific genome editing tasks.
The Importance of Innovation in Delivery
Innovative solutions are critical for addressing the delivery challenges of genome editing. The Innovative Genomics Institute at Berkeley and UCSF is at the forefront of these efforts, exploring various approaches.
Tyrosinase-Enabled Linking of Proteins
A novel method using tyrosinase to link CRISPR-Cas9 with cell-penetrating peptides has been developed, allowing efficient genome editing without additional cell manipulation.
Virus Capsid-Mediated Delivery
Leveraging viruses’ natural targeting abilities, scientists are modifying viral capsids for CRISPR-Cas9 delivery. These modified capsids can selectively edit specific cell types, as demonstrated in recent experiments with immune cells.
Clinical Applications on the Horizon
CRISPR-Cas9 shows promise in treating blood disorders such as sickle cell disease and beta thalassemia, with clinical trials demonstrating its safety and efficacy in editing immune cells for cancer patients.
Ongoing Research and Developments
Research continues to expand the CRISPR-Cas protein toolbox and RNA-guided gene regulation. Efforts are focused on delivery and control mechanisms, including chemical, societal, and regulatory aspects. New CRISPR systems and beyond are being explored in collaboration with Jill Banfield’s lab, highlighting the dynamic nature of this field.
Conclusion
The field of genome editing, spearheaded by Jennifer Doudna’s work with CRISPR-Cas9, is rapidly evolving, marked by exciting developments in delivery methods and clinical applications. The ongoing research and collaboration promise further breakthroughs, cementing CRISPR-Cas9’s role at the forefront of scientific innovation and societal discourse. As we advance, the responsibility to harness this powerful technology ethically and safely remains paramount, ensuring its benefits are realized while mitigating potential risks.
CRISPR technology has revolutionized genetic engineering, enabling precise DNA modifications with potential for treating genetic diseases and developing novel therapies, but ethical and regulatory considerations are essential. CRISPR's versatility extends beyond DNA editing, with applications in RNA targeting and genome editing in various organisms, raising ethical questions about its use...
CRISPR-Cas9 technology revolutionized gene editing with its precise modifications of DNA, but raises ethical questions regarding its use and potential consequences. Scientists, audiences, and regulators must engage in responsible discussions to guide ethical development and application of CRISPR....
CRISPR-Cas9, a revolutionary gene-editing technology, allows precise editing of DNA, with applications in treating genetic diseases, enhancing agricultural practices, and potentially improving human traits. CRISPR-Cas9 can be used to make targeted changes in the microbiome, potentially benefiting human health and reducing environmental impact....
The CRISPR-Cas9 system, pioneered by Jennifer Doudna, revolutionized genome editing with its ability to target specific DNA sequences, opening up new avenues in biomedical research and gene therapy. CRISPR-Cas9's dual RNA-guided DNA cleaving mechanism enables precise genome editing and has profound implications in the fields of medicine and genetics....
CRISPR-Cas9 revolutionizes genetic engineering with precise DNA editing, offering medical and agricultural advancements, but also raises ethical concerns, particularly around human germline editing. Addressing ethical dilemmas, technical challenges, and ensuring responsible use are crucial as the technology continues to evolve....
CRISPR-Cas9, pioneered by Jennifer Doudna, revolutionized gene editing, enabling precise DNA manipulation with implications for medicine, agriculture, and research. The technology's ethical considerations, such as germline editing and designer babies, necessitate responsible progress and discussion....
CRISPR, a revolutionary gene-editing technology, has profound ethical, scientific, and regulatory implications, particularly in the context of human genome editing. The ease of access and accessibility of CRISPR raise concerns about potential misuse and the need for balancing scientific progress with responsible use....